Static Magnetic Field Exposure Reproduces Cellular Effects of the Parkinson's Disease Drug Candidate ZM241385

Moderate strength (0.23–0.28 T) static magnetic fields (SMF) modulate signaling and differentiation in human embryonic cells

(2009) Zhiyun Wang et al.   BMC GENOMICS

A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity

(2009) Vincenzo Belcastro et al.   EXPERIMENTAL NEUROLOGY

Toxic effects of dopamine metabolism in Parkinson's disease

(2009) Nobutaka Hattori et al.   PARKINSONISM & RELATED DISORDERS

Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease

(2008) Alim Louis Benabid et al.   LANCET NEUROLOGY

Levodopa for the Treatment of Parkinson's Disease

(2008) Peter A. LeWitt   NEW ENGLAND JOURNAL OF MEDICINE

The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist

(2008) V.-P. Jaakola et al.   SCIENCE

Effect of 6mT static magnetic field on the bcl-2, bax, p53 and hsp70 expression in freshly isolated and in vitro aged human lymphocytes

(2008) B. Tenuzzo et al.   TISSUE & CELL

Spatial gradient effects of 120 mT static magnetic field on endothelial tubular formation in vitro

(2007) Hideyuki Okano et al.   BIOELECTROMAGNETICS

Static Magnetic Field Therapy: A Critical Review of Treatment Parameters

(2007) Agatha P. Colbert et al.   Evidence-based Complementary and Alternative Medicine

Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies

(2007) Reinaldo Naoto Takahashi   Frontiers in Bioscience-Landmark